Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Olema Pharmaceuticals, Inc. OLMA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
59/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$42.50
+160.7%

Olema Pharmaceuticals, Inc. (OLMA) is a Biotechnology company in the Healthcare sector, currently trading at $16.30. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is OLMA = $43 (+160.7% upside).

Valuation: OLMA trades at a trailing Price-to-Earnings (P/E) of -8.8 (S&P 500 average ~25).

Net income is $162M (loss), growing at -17.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $479M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 9.95 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $533M.

Analyst outlook: 8 / 8 analysts rate OLMA as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$42.50
▲ 160.74% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Olema Pharmaceuticals, Inc., the average price target is $42.50, with a high forecast of $48.00, and a low forecast of $38.00.
Highest Price Target
$48.00
Average Price Target
$42.50
Lowest Price Target
$38.00

OLMA SharesGrow Score Overview

71/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OLMA

✓
VALUE Pass
100/100
OLMA trades at a trailing Price-to-Earnings (P/E) of -8.8 (S&P 500 average ~25). Forward PEG -0.88 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $43, implying +163.8% from the current price $16. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
OLMA: +0%/yr revenue is, -17.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet OLMA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 9.95 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
OLMA: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 8 / 8 analysts rate OLMA as buy (100%). Analyst consensus target is $43 (+163.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.86-36.259
Volume769.97K
Avg Volume (30D)1.62M
Market Cap$1.42B
Beta (1Y)2.18
Share Statistics
EPS (TTM)-1.87
Shares Outstanding$87.01M
IPO Date2020-11-19
Employees96
CEOSean Bohen
Financial Highlights & Ratios
EBITDA$-178.21M
Net Income$-162.45M
Operating Income$-178.7M
Total Cash$505.44M
Total Debt$1.19M
Net Debt$-47.11M
Total Assets$533.43M
Price / Earnings (P/E)-8.7
Analyst Forecast
1Y Price Target$41.50
Target High$48.00
Target Low$38.00
Upside+154.6%
Rating ConsensusBuy
Analysts Covering8
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS68062P1066

Price Chart

Track all markets on TradingView
OLMA
Olema Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.86 52WK RANGE 36.26

People Also View

CNTA
CNTA
Centessa Pharmaceuticals plc
$39.59
+0.05%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 IRON
IRON
Disc Medicine, Inc.
$70.48
+2.95%
 PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.69
+2.23%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message